Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
Status:
Completed
Trial end date:
2018-09-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of Arotinolol Hydrochloride
and Metoprolol succinate on morning blood pressure, heart rate and target organ damage in
patients with essential hypertension. To provide evidence for hypertension treatment.
A group: Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks. B group: Metoprolol
succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.